Zobrazeno 1 - 10
of 53
pro vyhledávání: '"Naotake Tanaka"'
Autor:
Yoshiaki Maru, Naotake Tanaka, Yasutoshi Tatsumi, Yuki Nakamura, Makiko Itami, Yoshitaka Hippo
Publikováno v:
Oncogenesis, Vol 10, Iss 6, Pp 1-12 (2021)
Abstract KRAS, an oncogene, is frequently activated by mutations in many cancers. Kras-driven adenocarcinoma development in the lung, pancreas, and biliary tract has been extensively studied using gene targeting in mice. By taking the organoid- and a
Externí odkaz:
https://doaj.org/article/7e136c1af7b34a5ab5c76e496fc1c660
Autor:
Takako Kusanishi, Naotake Tanaka, Mizue Itoi, Miwa Ijiri, Keiko Ebisawa, Kiyomi Suzuka, Youko Hagiwara, Tukasa Yonemoto, Akinobu Araki, Makiko Itami
Publikováno v:
International Cancer Conference Journal.
Laparoscopic surgery for endometrial cancer using trocar insertion into the posterior vaginal fornix
Autor:
Miwa Ijiri, Keiko Ebisawa, Yuma Goto, Mizue Itoi, Takako Kusanishi, Kiyomi Suzuka, Naotake Tanaka
Publikováno v:
JAPANESE JOURNAL OF GYNECOLOGIC AND OBSTETRIC ENDOSCOPY. 38:233-238
Autor:
Makiko Itami, Takahiro Sugiyama, Naotake Tanaka, Yoshitaka Hippo, Yoshiaki Maru, Keiko Ebisawa
Publikováno v:
Journal of Obstetrics and Gynaecology Research. 47:2551-2554
Cervical clear cell carcinoma (CCCC) is rare. This report describes the case of CCCC with a serous component. A 22-year-old woman presented with vaginal bleeding. A cervical tumor was discovered: pelvic magnetic resonance imaging revealed a tumor mea
Autor:
Naotake Tanaka, Yuki Nakamura, Makiko Itami, Yoshitaka Hippo, Yasutoshi Tatsumi, Yoshiaki Maru
Publikováno v:
Oncogenesis, Vol 10, Iss 6, Pp 1-12 (2021)
Oncogenesis
Oncogenesis
KRAS, an oncogene, is frequently activated by mutations in many cancers. Kras-driven adenocarcinoma development in the lung, pancreas, and biliary tract has been extensively studied using gene targeting in mice. By taking the organoid- and allograft-
Autor:
Yuki Nakamura, Naotake Tanaka, Makiko Itami, Yoshiaki Maru, Yoshitaka Hippo, Tetsuo Noda, Ryoji Yao, Yasutoshi Tatsumi
Publikováno v:
The Journal of pathologyReferences. 255(2)
Genetically engineered mice have been the gold standard in modeling tumor development. Recent studies have demonstrated that genetically engineered organoids can develop subcutaneous tumors in immunocompromised mice, at least for organs that prefer p
Autor:
Naotake Tanaka, Yoshiaki Maru, Akiko Odaka, Keiko Ebisawa, Takahiro Sugiyama, Yoshitaka Hippo, Makiko Itami
Publikováno v:
Cancer Science
Cervical clear cell carcinoma (cCCC) constitutes an extremely rare subtype of cervical cancer. Consequently, its pathogenesis remains largely unknown, with no cell lines established from primary tumors. Here, we report the first establishment of cCCC
Autor:
Toshiyuki Seki, Shinichi Tate, Kyoko Nishikimi, Yoichi Unno, Mizue Itoi, Sadatomo Ikeda, Nobuhisa Yoshikawa, Hidehiko Akashi, Eitaro Suzuki, Naotake Tanaka, Takashi Hirakawa, Hiroaki Kajiyama, Hirokuni Takano, Kosuke Yoshihara, Aikou Okamoto, Makio Shozu
Publikováno v:
Journal of Clinical Oncology. 40:5502-5502
5502 Background: Advanced ovarian clear cell carcinoma (ACCC, stage III/IV disease) is a rare tumor characterized by chemoresistance. Bevacizumab (Bev) was approved in November 2013 in Japan and became incorporated in the treatment of advanced ovaria
Autor:
Sana Yokoi, Dong Hang, Yongyong Shi, Atsushi Takahashi, Seiichiro Mori, Zhibin Hu, Fumihiko Takeuchi, Ding Ma, Zhiqiang Li, Keitaro Matsuo, Michiaki Kubo, Iwao Kukimoto, Fumihiko Matsuda, Ni Li, Peng Wu, Yoichiro Kamatani, Shuang Li, Jianhua Chen, Mika Mizuno, Naotake Tanaka, Shusaku Inoue, Makoto Kuroda
Publikováno v:
Human Molecular Genetics. 28:341-348
The development of cervical cancer is initiated by human papillomavirus (HPV) infection and involves both viral and host genetic factors. Genome-wide association studies (GWAS) of cervical cancer have identified associations in the HLA locus and two
Autor:
Ashish Suri, Hidekatsu Nakai, Hideki Tokunaga, Shuuji Sumino, Kazuhiro Takehara, Kosei Hasegawa, Kiyonori Miura, Yoichi Kase, Nobuhiro Takeshima, Naotake Tanaka, Shoji Nagao, Junzo Hamanishi, Takashi Matsumoto, Hidemichi Watari, Hiroaki Itamochi, Yoshihito Yokoyama, Kimio Ushijima, Motoki Matsuura
Publikováno v:
Journal of Gynecologic Oncology
OBJECTIVE The primary objective of this study was to evaluate the safety of niraparib 300 mg/day in Japanese patients with platinum-sensitive, relapsed ovarian cancer in a maintenance setting. METHODS Phase 2, multicenter, open-label, single-arm stud